DNDi will constantly strive to hold itself to the highest standards of accountability, transparency, and ethics.

With the objective to promote an alternative model that will enable a new environment for R&D for the most neglected diseases, DNDi will engage independent, academic experts to examine issues such as intellectual property, regulatory processes, access to knowledge, and economics in order to stimulate a new environment for R&D for neglected diseases.

The Board of Directors approves project selection and sets policies for intellectual property, financial control, and ethics. Specifically, as per the R&D Guideline, all clinical programmes are guided by international, regional, and local regulations and standards: Good Clinical Practice guidelines (GCP/ICH) and the Helsinki Declaration, following the basic principles for medical research involving human beings, and according to the local and external institutions review boards and local rules and regulations of the countries.